跳至主要内容
临床试验/NCT02612701
NCT02612701终止不适用

E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion

Cedars-Sinai Medical Center1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2015年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
入组人数
20
试验地点
1
主要终点
Myocardial Perfusion (change in capillary blood volume from baseline at 30 minutes)

研究概览

简要总结

E-cigarettes deliver nicotine by creating an aerosol of ultrafine particles. Many questions remain about the size and composition and especially about the potential toxicity of these particles. Thus, a key unanswered question-and the research question proposed-is whether e-cigarette aerosol triggers the same acute impairment in coronary microvessel function as does conventional cigarette smoke, which delivers a very well-defined exposure to fine particles and many fold greater exposure to toxic (combustion) products including volatile organic compounds (such as acrolein) that have been implicated in the pathogenesis of tobacco-related coronary disease.

Because the effects of nicotine on the human coronary microcirculation remain incompletely defined-with multiple potential vasodilator and vasoconstrictor actions each of which may vary by dose-we will determine the comparative effects of conventional cigarette smoke against e-cigarette aerosol with no nicotine, with low-dose nicotine, and with high-dose nicotine.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 49 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Age 18-49
  • •Regular cigarette smoker defined as at least 1 pack year and ≥ 5/day
  • •E-cigarette smoker defined as ≥ 1/week in the last 6 months.

排除标准

  • •Sub-optimal echocardiography images as determined by the sonographer and/or investigators.
  • •History of cardiopulmonary (including asthma or use of inhalers),
  • •History of diabetes or dyslipidemia
  • •History of psychiatric illness
  • •Blood Pressure > 140/90
  • •Body Mass Index ≤ 18.5 or ≥ 30 kg•m2
  • •Evidence of any of the above by physical examination, Electrocardiogram (ECG) or echocardiogram
  • •Resting Heart Rate > 100 beats/min
  • •Cardiac rhythm disorder, specifically: rhythm other than sinus, Supraventricular Tachycardia (SVT), atrial fibrillation, ventricular tachycardia
  • •Use of prescription medication except oral contraceptive pills
  • •History of illicit drug use (self-stated)
  • •Any other condition(s) deemed by the physician investigators that put subjects at risk for participating in the study

研究组 & 干预措施

E-cigarettes (high nicotine e-liquid)

Experimental

Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking high concentration (18-24 mg/mL) e-cigarette liquid.

干预措施: E-cigarettes (high nicotine e-liquid) (Other)

Cigarettes

Experimental

Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking two standard cigarettes

干预措施: Cigarettes (Other)

E-cigarettes (nicotine free e-liquid)

Experimental

Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking nicotine free e-cigarette liquid.

干预措施: E-cigarettes (nicotine free e-liquid) (Other)

E-cigarettes (low nicotine e-liquid)

Experimental

Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking low concentration(4-6 mg/mL) e-cigarette liquid.

干预措施: E-cigarettes (low nicotine e-liquid) (Other)

结局指标

主要结局

Myocardial Perfusion (change in capillary blood volume from baseline at 30 minutes)

时间窗: Baseline and 30 minutes after smoking

Myocardial contrast echocardiography will be used to measure regional myocardial perfusion - capillary blood volume

Myocardial Perfusion (change in microvascular flux rate from baseline at 30 minutes)

时间窗: Baseline and 30 minutes after smoking

Myocardial contrast echocardiography will be used to measure regional myocardial perfusion - microvascular flux rate

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Florian Rader

M.D, M.Sc.

Cedars-Sinai Medical Center

研究点 (1)

Loading locations...

相似试验